Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Current Deferred Revenue (2018 - 2025)

10x Genomics' Current Deferred Revenue history spans 8 years, with the latest figure at $23.9 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 27.94% year-over-year to $23.9 million; the TTM value through Dec 2025 reached $23.9 million, down 27.94%, while the annual FY2025 figure was $23.9 million, 27.94% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $23.9 million at 10x Genomics, down from $33.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $33.2 million in Q4 2024 and bottomed at $5.3 million in Q2 2021.
  • The 5-year median for Current Deferred Revenue is $14.3 million (2023), against an average of $16.8 million.
  • The largest annual shift saw Current Deferred Revenue surged 165.57% in 2023 before it fell 27.94% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $7.7 million in 2021, then soared by 43.5% to $11.0 million in 2022, then surged by 99.09% to $22.0 million in 2023, then surged by 51.02% to $33.2 million in 2024, then decreased by 27.94% to $23.9 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Current Deferred Revenue are $23.9 million (Q4 2025), $33.0 million (Q3 2025), and $32.7 million (Q2 2025).